Agnistabio Inc

By leveraging AI platform, AgnistaBio can solve challenging translational research and drug discovery problems (make impossible possible):(1) swiftly identify regulating proteins/enzymes against the target protein of interest (including dynamic interacting 4D structure for accelerating drug design) on a proteome scale in days,(2) discover highly developable human antibody against target proteins of interest, including untargetable GPCRs, cryptic or multiprotein complex epitopes, and determine its epitope/paratope at atom level in just weeks. The promise of AgnistaAI-enabled drug discovery is speed, cost-effective, quality and novelty of the molecule, and higher probability of success. Collaboration is our key business model. Any types of collaboration are welcome.